These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 17275428

  • 1. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD.
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [Abstract] [Full Text] [Related]

  • 2. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.
    Transplant Proc; 2010 Mar; 42(1):35-8. PubMed ID: 20172276
    [Abstract] [Full Text] [Related]

  • 3. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M, Weppler D, Mittal N, Nishida S, Kato T, Tzakis A, Ruiz P.
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [Abstract] [Full Text] [Related]

  • 4. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
    Tzakis AG, Kato T, Nishida S, Levi DM, Madariaga JR, Nery JR, Mittal N, Regev A, Cantwell P, Gyamfi A, Weppler D, Miller J, Tryphonopoulos P, Ruiz P.
    Transplantation; 2003 Apr 27; 75(8):1227-31. PubMed ID: 12717207
    [Abstract] [Full Text] [Related]

  • 5. Intestinal and multivisceral transplantation immunosuppression protocols--literature review.
    Trevizol AP, David AI, Dias ER, Mantovani D, Pécora R, D'Albuquerque LA.
    Transplant Proc; 2012 Oct 27; 44(8):2445-8. PubMed ID: 23026616
    [Abstract] [Full Text] [Related]

  • 6. Results of intestinal and multivisceral transplantation in adult patients: Italian experience.
    Lauro A, Dazzi A, Ercolani G, Cescon M, D'Errico A, Di Simone M, Grazi GL, Vivarelli M, Varotti G, De Ruvo N, Masetti M, Cautero N, Di Benedetto F, Siniscalchi A, Begliomini B, Lazzarotto T, Faenza S, Pironi L, Pinna AD.
    Transplant Proc; 2006 Oct 27; 38(6):1696-8. PubMed ID: 16908252
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 27; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 8. Campath-1H in intestinal and multivisceral transplantation: preliminary data.
    Tzakis AG, Kato T, Nishida S, Levi D, Madariaga J, De Faria W, Nery J, Neff G, Kirk AD, Ruiz P.
    Transplant Proc; 2002 May 27; 34(3):937. PubMed ID: 12034248
    [No Abstract] [Full Text] [Related]

  • 9. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
    Tzakis AG, Kato T, Nishida S, Levi DM, Tryphonopoulos P, Madariaga JR, De Faria W, Nery JR, Regev A, Vianna R, Miller J, Esquenazi V, Weppler D, Ruiz P.
    Transplantation; 2003 May 15; 75(9):1512-7. PubMed ID: 12792506
    [Abstract] [Full Text] [Related]

  • 10. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S, Dew MA, Pilewski JM, DeVito Dabbs AJ, Zaldonis DB, Studer SM, Crespo MM, Toyoda Y, Bermudez CA, McCurry KR.
    J Heart Lung Transplant; 2011 Jul 15; 30(7):743-54. PubMed ID: 21420318
    [Abstract] [Full Text] [Related]

  • 11. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Sep 15; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 13. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.
    J Pediatr Surg; 2005 Jan 15; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 15. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, Gordon RD.
    Clin Transplant; 2005 Jun 15; 19(3):340-5. PubMed ID: 15877795
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E, D'Alessandro AM, Knechtle SJ, Odorico J, Becker Y, Pirsch J, Sollinger H, Fernandez LA.
    Transpl Int; 2008 Jul 15; 21(7):625-36. PubMed ID: 18397178
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ.
    Transplantation; 2009 Sep 27; 88(6):810-9. PubMed ID: 19920781
    [Abstract] [Full Text] [Related]

  • 19. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance.
    Abu-Elmagd KM, Costa G, Bond GJ, Wu T, Murase N, Zeevi A, Simmons R, Soltys K, Sindhi R, Stein W, Demetris A, Mazariegos G.
    Transpl Int; 2009 Jan 27; 22(1):96-109. PubMed ID: 18954362
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B, Shoemaker L, Recto M, Austin E, Dowling R.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):242-4. PubMed ID: 18267235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.